stratum corneum chymotryptic enzyme inhibitor (Arexis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namestratum corneum chymotryptic enzyme inhibitor (Arexis)
Drug Alias NameSCCE inhibitor (Arexis)SCCE inhibitor (Biovitrum)stratum corneum chymotryptic enzyme inhibitor (Biovitrum)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKallikrein-7 inhibitors
TargetsKallikrein-7
Therapy Area/IndicationsDermatitis, AtopicNetherton Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArexis AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArexis AB
Active IndicationsN/A
Inactive IndicationsDermatitis, AtopicNetherton Syndrome

Other Information

ATC CodeN/A
Related LinksN/A